Valeant Pharmaceuticals International, Inc. (VRX)
-NYSE 86.41 
0.55(0.64%) 04:05 SGT|After Hours
:
86.51 0.10 (0.12%) 04:49 SGT
| Prev Close: | 85.86 |
|---|
| Open: | 86.20 |
|---|
| Bid: | 82.59 x 100 |
|---|
| Ask: | 86.69 x 100 |
|---|
| 1y Target Est: | 52.38 |
|---|
| Beta: | 0.94 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 85.62 - 87.55 |
|---|
| 52wk Range: | 42.47 - 96.25 |
|---|
| Volume: | 8,347,277 |
|---|
| Avg Vol (3m): | 1,858,750 |
|---|
| Market Cap: | 26.43B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.43 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Valeant Raising FundsZacks(Thu, 04:55 SGT)
- Valeant Pharma plans $1.75B stock offeringAP(Tue, 18 Jun)
- Analysts raise estimates on Valeant PharmaAP(Thu, 30 May)
- Tiffany, Tesla, Michael Kors are big moversAP(Wed, 29 May)
- Ahead of the Bell: Valeant Pharma shares climbAP(Tue, 28 May)
- Valeant to buy Bausch + Lomb for $8.7BAP(Tue, 28 May)
- Canada drugmaker Valeant to buy Bausch & Lomb for $8.7 billionat Reuters(Tue, 28 May)
- News Summary: Valeant to buy Bausch + LombAP(Mon, 27 May)
- Valeant shares jump on Bausch & Lomb deal rumorAP(Sun, 26 May)
- Actavis buying Warner Chilcott in $8.5B dealAP(Tue, 21 May)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6.99 |
|---|
| Ex-Dividend Date: | 10-Nov-10 |
|---|
Analysts
| Annual EPS Est
(Dec-10)
: | N/A |
|---|
| Quarterly EPS Est
(Sep-10)
: | N/A |
|---|
| Mean Recommendation*: | 3.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics.
View More